Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Carole Ho Sells 12,255 Shares of Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Carole Ho sold 12,255 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $247,796.10. Following the sale, the insider now owns 178,580 shares of the company’s stock, valued at $3,610,887.60. This represents a 6.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI opened at $21.25 on Thursday. Denali Therapeutics Inc. has a fifty-two week low of $14.56 and a fifty-two week high of $33.33. The company has a market cap of $3.06 billion, a price-to-earnings ratio of -7.70 and a beta of 1.39. The business’s 50 day moving average price is $24.34 and its 200-day moving average price is $24.88.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the previous year, the company posted ($0.72) EPS. Sell-side analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Hedge Funds Weigh In On Denali Therapeutics

A number of institutional investors have recently modified their holdings of the stock. MONECO Advisors LLC grew its position in shares of Denali Therapeutics by 4.6% during the 3rd quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock worth $265,000 after buying an additional 400 shares in the last quarter. Assetmark Inc. boosted its position in Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after purchasing an additional 580 shares in the last quarter. CWM LLC lifted its position in shares of Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after buying an additional 654 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Denali Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after acquiring an additional 920 shares during the period. Finally, Quest Partners LLC purchased a new position in Denali Therapeutics in the 3rd quarter worth $73,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. HC Wainwright lowered their target price on shares of Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a report on Tuesday. Jefferies Financial Group increased their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 1st. William Blair began coverage on Denali Therapeutics in a research report on Friday, January 3rd. They set an “outperform” rating for the company. Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Finally, Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.91.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.